Details of issuance or disposal
Issuance and exercise status report for stock acquisition rights issued through a third-party allotment, with an option to amend the exercise price
Shares delivered during the month under review: 630,300 shares (new shares). Shares corresponding to the 8,144 stock acquisition rights exercised in full: Not disclosed. Transferred treasury shares: 0 shares.
The lower thin line represents the existing number of shares to which these shares will be added.
Amount raised: ¥590,920,400. Approximate net proceeds: Not disclosed.
Exercise ratio subject to exercise restrictions: 9.7% (664,600 shares delivered across all series combined / 6,884,900 listed shares outstanding as of the payment date for the issuance). Dilution rate for the 15th Series Stock Acquisition Rights alone: Not disclosed.
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance and exercise status report for stock acquisition rights issued through a third-party allotment, with an option to amend the exercise price |
| Number of shares to be issued or disposed of | Shares delivered during the month under review: 630,300 shares (new shares). Shares corresponding to the 8,144 stock acquisition rights exercised in full: Not disclosed. Transferred treasury shares: 0 shares. |
| Amount of funds to be raised | Amount raised: ¥590,920,400. Approximate net proceeds: Not disclosed. |
| Intended allottee | Cantor Fitzgerald Europe (8,144 rights) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 9.7% (664,600 shares delivered across all series combined / 6,884,900 listed shares outstanding as of the payment date for the issuance). Dilution rate for the 15th Series Stock Acquisition Rights alone: Not disclosed. |
| Total number of issued shares | 7,069,000 shares (as of 28 February 2026) → Not disclosed |
| Exercise price | Exercise price: ¥741. Whether an amendment provision applies and the lower limit of any amendment: Not disclosed. |
| Number of Stock Acquisition Rights | Total number issued: 8,144 rights. Unexercised balance: 0 rights. Number exercised during the month under review: 6,303 rights. |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations. The exercise ratio subject to the restrictions is 9.7%. |
| Most recent equity financing | 26 December 2025: Issuance of the 15th Series Stock Acquisition Rights (with option to amend the exercise price); amount raised: ¥590,920,400 |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.As all of these stock acquisition rights had been fully exercised, the company disclosed their monthly exercise status for March 2026 together with the completion of exercise.